China’s recently finalization of data protection regulations and establishment of a new National Data Bureau following the recent “Two Sessions” political meetings usher in a new chapter in the country’s security-focused regulatory environment, in which health players must pay close attention to avoid mishaps and non-compliance.
Navigating through China’s personal data protection maze is becoming increasingly important as the country emphasizes national security over economic development and strengthens the oversight of such information.
Recent moves by Beijing show that rules governing the cross-border transfer of personal information are now receiving a final overhaul...
Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.
In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.
The proportion of China-originated drugs granted expedited reviews in China doubled in the first half of this year, Pharmaprojects data show, surpassing those receiving similar treatment in the US and likely driven by multiple factors.
